Evidence for involvement of spinal RANTES in the antinociceptive effects of triptolide, a diterpene triepoxide, in a rat model of bone cancer pain

Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):477-80. doi: 10.1111/bcpt.12265. Epub 2014 May 24.

Abstract

It has been shown that triptolide has beneficial effects in the treatment of neuropathic pain, but its effects on bone cancer pain (BCP) remain unclear. In this study, we aimed to explore the potential role of spinal regulated activation of normal T cell expressed and secreted (RANTES) in the antinociceptive effects of triptolide on BCP. A BCP model was induced by injecting Walker 256 mammary gland carcinoma cells into the intramedullary space of rat tibia. Intrathecal administration of triptolide (0.5, 1, 2 μg) could dose-dependently alleviate mechanical hyperalgesia and spontaneous pain. In addition, there were also concomitant decreases in RANTES mRNA and protein expression levels in spinal dorsal horn. These results suggest that the antinociceptive effects of triptolide are related with inhibition of spinal RANTES expression in BCP rats. The findings of this study may provide a promising drug for the treatment of BCP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Blotting, Western
  • Bone Neoplasms / complications*
  • Carcinoma 256, Walker
  • Chemokine CCL5 / antagonists & inhibitors*
  • Disease Models, Animal
  • Diterpenes / pharmacology*
  • Epoxy Compounds / pharmacology
  • Female
  • Neoplasm Transplantation
  • Pain / drug therapy*
  • Pain / etiology
  • Pain Measurement
  • Phenanthrenes / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Real-Time Polymerase Chain Reaction
  • Spinal Cord / metabolism
  • Spinal Cord / physiology

Substances

  • Analgesics
  • Chemokine CCL5
  • Diterpenes
  • Epoxy Compounds
  • Phenanthrenes
  • triptolide